The project in a nutshell
Testing to see if genetic markers in the blood of men with
prostate cancer can be used to help doctors assess how individuals
respond to new treatments and which treatments would work best.
Why we funded it
Doctors usually rely on changes in PSA to
check whether a new treatment is effective or not. PSA is the best
test currently available but has many limitations. Tumours release
mutated DNA into the blood stream which can be counted using the
latest technology. Changes in the mutation count during treatment
may more accurately reflect how well a treatment is working than a
PSA test, which could lead to more prostate cancer treatments and
more personalised medicine.
For more detailed information on this project, please look at